However, this meta-analysis showed that the standard DAPT was associated with a higher risk of major bleeding in patients with acute coronary syndrome compared with the short-term DAPT, and the discrimination was even more pronounced when the study was limited to enroll only patients with acute coronary syndrome, including a novel P2Y12 inhibitor, monotherapy after short-term DAPT with ticagrelor, and short-term DAPT for ≤3 months. The gene discussed is P2RY12; the disease is acute coronary syndrome.